The U.S. Food and Drug Administration is reminding the public that stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. still may be on the market. Evidence gathered to date suggests that the stolen insulin was not stored and handled properly and may be dangerous for people to use. The FDA has received multiple reports of patients who suffered an adverse event due to poor control of glucose levels after using a vial from one of the stolen lots. When the FDA first alerted the public to the theft in June, it reported that three lots of Levemir totaling 129, 000 vials had been stolen in North Carolina. So far only about 2 percent of the total amount stolen has been recovered.
More than six million people in the U.S. suffer from persistent wounds - open sores that never seem to heal or, once apparently healed, return with a vengeance. The bedridden elderly and infirm are prone to painful and dangerous pressure ulcers, and diabetics are susceptible to wounds caused by a lack of blood flow to the extremities. "The problem is chronic, " says Prof. Amihay Freeman of TAU's Department of Molecular Microbiology and Biotechnology. To solve it, he's developed a unique device that uses a solution to whisk away dead tissue, bathing the wound while keeping dangerous bacteria away. Prof. Freeman's "Dermastream" provides an enzyme-based solution that flows continuously over the wound, offering an alternative treatment to combat a problem for which current treatments are costly and labor-intensive.
In 2009 Diabetes UK will be running a pilot internship scheme at our central office in London. Applications are now open, so if you would like to gain experience of working in the charity sector then read on. Our internship scheme is open to anyone who can commit to a 12-week volunteer placement. All placements are project-based and will give you real responsibility and the opportunity to apply your knowledge in a practical way. You will gain valuable work experience, develop new skills and learn how one of the UK's largest charities is run. An integral part of the team Interns will generally work between three and five days a week, with flexible hours.
Blood glucose meters that use GDH-PQQ (glucose dehydrogenase pyrroloquinoline quinone) test strips can produce false results that lead to excessive use of insulin in patients receiving treatments containing certain non-glucose sugars, said the US Food and Drug Administration (FDA) last Friday. If these non-glucose sugars are in a sample of patients' blood that is tested using a GDH-PQQ glucose test strip it could prompt inappropriate clinical action such as giving patients too much insulin, "potentially resulting in hypoglycemia, coma, or death", said the FDA in a Public Health Notification. There is also the added risk that cases of actual hypoglycemia (lower than normal blood glucose) may go unnoticed if patients and their carers rely soley on results produced with devices that use GDH-PQQ glucose test strips, said the FDA.
The U.S. Food and Drug Administration (FDA) today advised health care practitioners and patients against using certain glucose monitoring technology that employs a specific test strip when the patients are also receiving therapeutic products containing non-glucose sugars. Non-glucose sugars contained in some therapeutic products such as peritoneal dialysis solutions and certain immunoglobulins can falsely elevate glucose results, which may prompt excessive insulin administration. These therapeutic products, which are labeled to indicate that they may interfere with this particular glucose monitoring technology, are mostly used in patients with serious medical conditions, including kidney failure and moderate to severe rheumatoid arthritis.
Cardium Therapeutics (NYSE Amex: CXM) announced that all patients enrolled in the Company's MATRIX clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009. The Phase 2b MATRIX clinical trial is a prospective, randomized, double-blind, placebo-controlled study of Excellarate(TM) for the potential treatment of chronic diabetic foot ulcers. The clinical study is designed to evaluate safety and key efficacy measures including complete wound closure, time to complete wound closure, absolute and percent change in ulcer area, and wound healing trajectories at various time points, as well as a wide range of other safety and comparative healing metrics which will be used to develop a Phase 3 clinical study.